Scribe Therapeutics, a biotechnology firm specializing in CRISPR gene-editing, has successfully launched its upsized initial public offering on the Nasdaq. The company priced 8,580,000 shares at $15.00 each, raising gross proceeds of approximately $128.7 million. This financial milestone will support its mission to develop in vivo genetic medicines for disease prevention and durable therapeutic intervention.
IPO Details and Market Debut
The offering was priced at the high end of its projected range, indicating robust investor confidence in the company's platform. Scribe Therapeutics is selling all 8,580,000 shares, generating substantial capital before underwriting discounts and expenses. This funding is crucial for advancing its clinical-stage programs and expanding research efforts.
The company's common stock is scheduled to begin trading on the Nasdaq Global Market on July 24, 2026, under the ticker "SCTX". The offering is anticipated to officially close on July 27, 2026, pending the satisfaction of customary closing conditions. This public debut marks a pivotal transition for the clinical-stage biotechnology firm.
Underwriters have a 30-day option to purchase up to an additional 1,287,000 shares at the initial offering price. This arrangement could potentially increase the total proceeds from the public offering. The transaction is managed by a syndicate of joint book-runners including Leerink Partners, Goldman Sachs & Co. LLC, Guggenheim Securities, and Wells Fargo Securities.
Strategic Private Placement with Sanofi
In a concurrent transaction, Scribe Therapeutics also secured a private placement with the global pharmaceutical company Sanofi. Sanofi has agreed to purchase 500,000 shares of common stock at the IPO price of $15.00 per share. This investment underscores the strength of the existing strategic collaboration between the two companies.
This private sale is separate from the public offering and will not be registered under the Securities Act of 1933. The placement is expected to close on the same day as the IPO, subject to its own closing conditions. The successful completion of the IPO is not contingent on the finalization of this private transaction.
Pioneering CRISPR-Based Genetic Medicines
Co-founded by Nobel laureate Jennifer Doudna, Scribe Therapeutics is at the forefront of engineering advanced CRISPR-based technologies. The company focuses on creating purpose-built in vivo genetic medicines designed to become standard treatments for prevalent diseases. Its goal is to extend healthy lifespans by addressing the root causes of illness.
The company's initial programs target key drivers of atherosclerotic cardiovascular disease (ASCVD), including elevated LDL-C and triglycerides. Utilizing its proprietary CRISPR by Design™ approach, Scribe aims to develop preventative treatments for cardiometabolic conditions. This focus addresses a significant area of unmet medical need affecting millions.
Scribe's lead candidate, STX-1150, is a novel therapy designed to epigenetically silence the PCSK9 gene to reduce harmful LDL-C levels. To accelerate its impact, the company has established key partnerships with industry leaders like Sanofi and Eli Lilly. These collaborations are instrumental in broadening the application of its engineered CRISPR technologies.
Scribe Therapeutics' successful IPO and concurrent private placement provide a substantial financial foundation to advance its pioneering work. The capital infusion will accelerate the development of its clinical pipeline, particularly its lead programs in cardiometabolic disease. With strong investor backing and strategic alliances, the company is well-positioned to translate its innovative CRISPR platform into transformative genetic medicines.